Company ProfilePremium

Alpha HPA Limited

Company Profile Analysis

Ticker: A4N.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Alpha HPA Limited - Company showcase

Year Founded & Workforce

2003

130 Employees

Alpha HPA Limited logo

Alpha HPA Limited Employee Contacts

3 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Alpha HPA Limited Overview

Alpha HPA is an Australian specialty advanced-materials manufacturer commercialising an exclusively licensed and company-consolidated solvent-extraction purification process, branded Smart SX Technology, which it describes as the first application of solvent extraction to aluminium purification. Rather than starting from energy-intensive aluminium metal, the process leaches a common aluminium hydroxide feedstock in nitric acid and refines it through ion exchange and solvent extraction into ultra-high-purity (4N5 to 5N) aluminas, aluminium hydroxide (ATH), aluminium nitrate and synthetic sapphire. A ~380 tpa Stage One plant has run continuously in Gladstone since late 2022 and is roughly three times oversubscribed; a ~10,000 tpa Stage Two plant — positioned as the world's largest single-site high-purity aluminium materials facility — is under construction for first production in late 2027. Its commercial thesis has pivoted decisively toward AI-driven semiconductor demand (thermal fillers, CMP slurries, fab ceramics), with sovereign-capital backing from NAIF, EFA, NRFC and QIC.


What the company does

Alpha HPA manufactures ultra-high-purity aluminium materials. Its company self-description in the FY2026 Annual Report characterises it as an Australian advanced-materials company that exclusively commercialises a scientific process for making ultra-high-purity aluminium materials for demanding high-technology industries, using Smart SX Technology to produce a growing portfolio of ultra-high-purity alumina, aluminium nitrate, aluminium hydroxide and synthetic sapphire material. The company states that the process uses a readily available industrial feedstock instead of aluminium metal, recycles almost all reagents and process streams, and produces materially lower emissions and waste than incumbent routes (FY2026 Annual Report, "About us").

The chemistry, as summarised by the NRFC in its January 2026 investment release, involves nitric-acid leaching of high-grade aluminium hydroxide, followed by ion exchange and solvent extraction to recover and separate aluminium nitrate at very high purity, which is then converted into an intermediate precursor and finally into HPA at lower temperatures than conventional processes. The adjacency to Orica's Yarwun plant creates a closed loop: Orica supplies reagents (principally nitric acid) and takes back by-products for reuse (NRFC release, January 2026).

Business model and revenue model

Revenue typeCurrent status (FY2026)Commentary
Product sales — high-purity aluminas, ATH, Al-nitrate, nano-dispersionsPrimary revenue source; A$747,150 total statutory sales revenue FY2026 including sapphireSold per kg in USD (weighted average ~US$25.86/kg ex-sapphire in the June 2026 quarter)
Product sales — synthetic sapphire (Alpha Sapphire)Small; sapphire sales up 425% year-on-year in FY2026 from a very low baseBoules and 200 mm wafers to an optics customer in Hong Kong/China and a semiconductor customer in Austria
Services / subscription——
LicensingNone outbound; Alpha is itself a licensee/owner of consolidated process IP—
Other incomeA$2.90 million FY2026 (A$3.11 million FY2025), principally grant income recognition and R&D incentivesNot operating revenue
Finance incomeA$3.51 million FY2026 (A$7.17 million FY2025) on cash balancesDeclines as cash is deployed into construction

The business model is that of a vertically integrated specialty-chemicals manufacturer selling technically qualified, customer-specific materials under business-to-business contracts. The company's risk disclosures note that pricing for its products is set through technically qualified B2B negotiation that is opaque and end-user specific — i.e., there is no exchange-traded benchmark price (FY2026 Annual Report, Governance and Risk table).

Effectively 100% of operating revenue is product revenue. The company is in a transitional "qualification sales" model: Stage One volumes are sold in kilogram-to-tonne lots to over 100 end-users for qualification and early commercial supply, with the explicit aim of converting non-binding Letters of Intent (LOIs) into binding offtake contracts for Stage Two.

Value-chain position

Alpha sits in the midstream of the aluminium-materials value chain: downstream of bulk alumina/aluminium hydroxide producers (its feedstock), upstream of materials formulators (spherical thermal-filler makers, CMP slurry formulators, technical-ceramics manufacturers, battery cathode/separator coaters, sapphire growers) and two or three steps removed from end OEMs (memory and logic chipmakers, AI accelerator packagers, battery cell makers, LED makers, luxury watch brands). Through Alpha Sapphire it also integrates one step further downstream into crystal growth.

Customer types and end-markets

End-marketApplicationAlpha differentiation claimed (company disclosure)
Semiconductors — thermal managementSpherical alumina thermal fillers and thermal interface materials (TIM) for AI processors and HBM packagingBelieved to be the only manufacturer globally producing ultra-low-alpha HPA and ATH with uranium and thorium below 1 ppb
Semiconductors — CMPNano-alumina slurries for hard-to-polish substrates (hard-carbon masks for HBM/DRAM, SiC wafers, alumina dielectric, tungsten and copper layers); 5N Al-nitrate as slurry additiveVery low alkali impurities (Na, K, Li) and unique particle morphology
Semiconductors — fine ceramics / fab toolsElectrostatic chucks, chamber components, thermal-spray coatings, interposers, thermal base platesUltra-low-alpha 4N+ alumina with high sintering density (>3.9 g/cm³)
Direct Lithium Extraction (DLE)Amorphous ATH as precursor for next-generation sorbentsCommercial-scale production of amorphous ATH
Lithium-ion batteriesAl-nitrate for battery coatings; cathode doping/coatingFirst to demonstrate commercial-scale 5N aluminium nitrate (company claim)
PharmaceuticalsGamma-phase alumina; bio-ceramics and dentalRegular low-volume, high-value sales to a South Korean pharmaceutical end-user
Synthetic sapphire / LED / opticsHPA tablets (Ultra TAB) as crystal-growth feedstock; own sapphire boules and wafers"Low-carbon" sapphire for Swiss watch market; 200 mm C-plane wafers for GaN-on-sapphire
CatalystsHigh-purity ATHQualified for up to 180 tpa; first sales in FY2026
Specialty coatings / aerospaceAl-nitrate for high-temperature coatingsFirst commercial shipment post-30 June 2026 to a European aerospace coatings maker
Water treatmentAl-nitrate for PFAS sorbentsUS research collaboration; seeking commercial partners

The FY2026 Annual Report identifies five priority application areas where management believes it has clear technical differentiation, plus several niche sectors:

Independent characterisation

Alpha HPA should be understood as a single-asset, single-technology industrial scale-up story whose investment case has migrated. At the time of the March 2020 Definitive Feasibility Study (DFS) and the May 2024 updated DFS, the dominant narrative was lithium-ion battery separator coatings and LED sapphire. By FY2026 the commercial pipeline is dominated by AI semiconductor supply chains, which (a) carry higher unit values and more stringent qualification barriers, and (b) value Alpha's ultra-low-alpha (U/Th <1 ppb) capability, which is a genuinely differentiated attribute if sustained at scale. Management itself acknowledges that the physical product slate is broadly unchanged from the DFS while the end-markets have shifted materially (FY2026 Annual Report, "Looking ahead"). The key unproven elements are (i) Stage Two execution and ramp-up at 25–30x Stage One scale, (ii) conversion of >12,000 tpa of non-binding LOIs into binding, priced offtake, and (iii) achieved pricing versus DFS assumptions.

Strategy

Stated strategy (themes from the FY2026 Annual Report)

Management frames the strategy around five themes, paraphrased: (1) transition from technology developer supplying qualification volumes to a scaled advanced-materials manufacturer; (2) concentrate commercial effort where Smart SX confers a clear technological edge — purity, ultra-low alpha emission, manufacturing flexibility and commercial-scale supply; (3) prioritise the AI/semiconductor supply chain (thermal management, CMP, fab ceramics) while retaining battery, pharmaceutical, catalyst and sapphire options; (4) position Australia as a manufacturer, not merely a supplier, of critical-mineral-derived advanced materials, aligned with government sovereign-capability policy; and (5) prepare for growth beyond Stage Two through Stage Three concept studies. The corporate vision and mission emphasise innovation for people and planet and high-performance materials delivered with quality, agility and care.

Strategic initiatives — last 24 months

InitiativeDateDescriptionTarget / KPIStatus
Stage Two HPA First constructionOngoing since 2024~10,000 tpa plant; 86 procurement packagesFirst production late 2027; budget A$699.2m75 of 86 packages awarded; 607,000 safe construction hours in FY2026; on budget/schedule vs Jan 2026 re-baseline
Stage Two re-baselineJan 2026Capex reset from A$553m to A$699.2m (+26%); completion late 2027–early 2028Hold budget and scheduleHolding as at July 2026
Stage One optimisation and expansionFY2026Nano mill, jet mill (>200 kg/day added), ATH debottlenecking, spray drying, ICP-OES labATH from 490 to >1,400 kg/week; Al-nitrate 900 to ~1,200 kg/day; tablets ~300 kg/week; complete Oct 2026Largely installed; completion targeted October 2026
CMP nano-slurry commercialisationFY2025–FY2027In-house nano-alumina dispersionCommercial supply FY2027First commercial orders; 11 formulators sampled
Semiconductor supply-chain entryFY2026Qualification with Japanese/Korean filler makers and US equipment makersConvert LOIs to contracts"Formal entry" claimed; contracts in advanced negotiation
Lithium-ion battery LOIFY2026Up to 5,000 tpa non-binding LOI with a Tier-1 battery customerDelivery schedule aligned to Stage TwoNegotiating delivery schedule
Stage Three concept studiesFY2026–Expansion beyond HPA First FacilityDemand model >50,000 tpa by 2030Concept phase
Funding stack completion2024–2026A$400m NAIF/EFA; A$225m equity; A$30m QIC; MMI-C and Qld IPP grantsFinancial Close; first drawFirst draw targeted Q4 CY2026
HSE system upgradeFY2026Evotix Assure HSE system expansion; critical-risk review; MHF safety caseZero recordable injuriesAchieved at Gladstone; one LTI at Brisbane PDC
Cyber maturityFY2026Gap assessment against SMB1001:2026 Gold; foreign-interference trainingCertificationIn progress

ESG commitments

HPA First is designed to operate on 100% renewable electricity; the NRFC cites roughly 70% lower emissions than traditional HPA manufacturing routes (NRFC CEO quoted in Grafa). Near-zero-waste reagent recycling with Orica. A 2026 Sustainability Report is referenced in the Annual Report (climate risk strategy).

Medium-term targets / guidance

Alpha does not issue revenue or earnings guidance. Operational targets disclosed: Stage One upgrades complete October 2026; spray-drying capacity doubled by December 2026; NAIF/EFA first draw Q4 CY2026; major procurement complete by Q1 2027; Stage Two first production late 2027; Al-nitrate supply to US Tier-1 CMP formulator from late CY2026; catalyst orders to multi-tonne levels in Q1 CY2027.

Products & Services

All products are produced from the same Smart SX aluminium-nitrate intermediate. Purity designations: 4N5 = 99.995%; 5N = 99.999%.

HPA First platform

Product (brand)Chemistry / phaseKey specifications & capabilities (company disclosure)Target customers / applicationsStatus / latest developmentPricing
Ultra AAP™Ultra-high-purity alpha-phase alumina powder (Al₂O₃), 4N5+Low U/Th (<1 ppb) for low-alpha emissionThermal fillers, LED, CMP, battery cathode doping, technical ceramicsIn Stage One production; Stage Two base case 3,200 tpa alpha-phase aluminaNot disclosed; June 2026 quarter blended ~US$25.86/kg ex-sapphire
Ultra AAP-X™Alpha-phase alumina powder, enhanced gradeTailored morphologyThermal management, fine ceramics, pharmaceuticalProduction / qualification—
Ultra AAP-DP™High-sintering alpha-phase alumina powder+4N5, sintered density >3.9 g/cm³Semiconductor ceramic tools (electrostatic chucks, hold-down rings, lifting arms), interposers, base platesRecently developed; second-round qualification with Japanese/Korean thermal-spray users; supplier onboarding with two US Tier-1 equipment makers—
Ultra AAP-D™Alpha alumina nano-dispersion (slurry)4N5+ nano-particles with novel crystallinity; strong removal rates on hard-to-polish layersCMP slurry formulators (HBM/DRAM hard-carbon masks, SiC wafers, dielectric, W and Cu layers)Final-generation samples sent to 11 formulators; first commercial orders (EU end-user); in-house nano-milling commissioned mid-2026; commercial supply expected FY2027—
Ultra GAP™Gamma-phase alumina powder4N5+Thermal fillers, CMP, Li-ion cathode doping/coating, catalystsStage Two base case 2,000 tpa gamma alumina—
Ultra GAP-X™Gamma-phase alumina, enhanced gradeCustomer-specificThermal management; pharmaceutical (S. Korea)Open orders >11 tonnes from Korean and Japanese semiconductor customers at July 2026—
Ultra ATH™Ultra-high-purity aluminium tri-hydroxide, Al(OH)₃4N5+; amorphous variant for DLEThermal fillers, DLE sorbent precursors, cathode dopants, catalysts, pharmaceuticalProduction rising from ~490 kg/week to >1,400 kg/week after Stage One upgrades; Stage Two base 1,700 tpa (upside 2,000 tpa)—
Ultra ALN™Aluminium nitrate nonahydrate crystal, Al(NO₃)₃·9H₂O, 5NCommercial-scale 5NCMP slurry additive, battery coatings, solid-state electrolytes, catalysts, thermal-spray coatings, micro-LED phosphors, aerospace coatings, PFAS sorbentsCommercial terms accepted with a US Tier-1 CMP slurry formulator (supply from late CY2026); Stage One output rising from 900 to ~1,200 kg/day; Stage Two base 3,500 tpa (upside 5,000 tpa)—
Nano-alumina powder (Ultra NAP)4N5+ nano Al₂O₃ powder—CMP, cathode coating, high-density sinteringStage Two base case 30 tpa—
Ultra TAB™Sintered HPA tablets / pucks5NSynthetic sapphire growers (Kyropoulos/other methods), opticsQualified with a sapphire optics end-user (Sep 2024 quarter); ~300 kg/week from Stage One inventory—
Pseudoboehmite / amorphous variantsAlumina hydratesHigh dispersibilitySemiconductor and research customersSample/research orders (US)—

Alpha Sapphire platform

ProductDescriptionCustomerStatus
Synthetic sapphire boulesGrown from Alpha's own HPA in two next-generation growth units (Ebner/Fametec technology)Primary optics customer (Hong Kong/China) supplying premium Swiss watchmakers; positioned as "low-carbon" sapphireOngoing sales; quality program reduced bubbles, cloud zones, low-angle grain defects; eliminated molybdenum contamination
200 mm C-plane sapphire wafersWide-format wafersAustrian semiconductor customer qualifying GaN-on-sapphire power/RF devicesAdditional orders received in FY2026

Product mix at Stage Two (base vs upside)

Product (tpa)May 2024 DFSUpside scenario (Jul 2026)
5N aluminium nitrate3,5005,000
4N5+ alpha-phase alumina3,2003,200
4N5+ gamma-phase alumina2,0002,000
4N5+ ATH1,7002,000
4N5+ nano-alumina3030
Total10,43012,230

Source: June 2026 Quarterly Activities Report. The upside scenario assumes a ~5% increase in aluminium nitrate production to service additional Al-nitrate and ATH sales, based on Stage One "as-built" performance.

Financial Narrative

Income statement

Source: FY2026 Remuneration Report, "Consequences of performance on shareholder wealth".

Source: FY2026 Annual Report, Consolidated Statement of Profit or Loss. EBITDA is analyst-derived.

Gross, operating, EBITDA and net margins are not meaningful: operating costs are roughly 60x sales revenue. Revenue CAGR is not computable on a like-for-like five-year basis from retrieved data; Stage One sales grew from A$56k (FY2024) to A$556k (FY2026), a two-year CAGR of approximately 215% (derived).

Commentary on trends and drivers. Losses have widened every year for five years — from A$7.4 million in FY2022 to A$42.7 million in FY2026 — tracking the build-out of an operating organisation (employee expenses up 25% to A$16.1 million in FY2026), the depreciation of Stage One (D&A up 64% to A$5.4 million as Stage One upgrades and the Brisbane centre were added), and non-cash share-based payments (A$5.1 million). The critical inflection in FY2026 was the halving of finance income (A$7.2 million to A$3.5 million) as cash was spent on Stage Two, despite the January 2026 raise. Revenue more than doubled but remains immaterial. Importantly, Stage Two construction costs are capitalised to property, plant and equipment, so the income statement understates the cash burn; the true economic picture is in the cash-flow statement.

Balance sheet

Source: FY2026 Annual Report, Consolidated Statement of Financial Position. Total debt and net cash are analyst-derived. There is no bank debt drawn: the A$400 million NAIF/EFA facilities had not reached Financial Close at 30 June 2026 and the June 2026 Appendix 4C shows loan facilities of nil, with only the A$30 million QIC "other" facility fully drawn.

Interim data point (Half-Year Report, 31 December 2025): cash A$45.1 million, total assets A$305.3 million, total equity A$205.8 million — illustrating how close to the funding edge the company ran ahead of the January 2026 placement (cash had fallen to ~A$39 million by 22 January 2026 per the placement announcement).

Cash flow

Sources: FY2026 — June 2026 quarter Appendix 4C (12-month year-to-date column). FY2025 operating cash flow — Macquarie Research flashnote, 29 July 2025.

Quarterly run-rate (FY2026): operating outflows of A$11.4 million (March quarter) and A$11.3 million (June quarter); capex of A$47.9 million (March quarter) and A$45.8 million (June quarter). On these run-rates the company is spending roughly A$57–60 million per quarter in total.

Ratios

Company-reported ROCE (loss ÷ (total assets − current liabilities)) for the five years: FY2022 -15%, FY2023 -28%, FY2024 -10%, FY2025 -14%, FY2026 -10% (FY2026 Remuneration Report).

ROIC and cash conversion cycle are not meaningful for a pre-production entity. ROE FY2025 uses opening equity of A$247.2 million (1 July 2024) from the Statement of Changes in Equity.

Commentary. The balance sheet transformed in FY2026: total assets rose 82% to A$514.9 million and PP&E more than doubled to A$292.5 million as Stage Two capital was deployed. Equity nearly doubled to A$411.1 million on the A$225 million placement plus A$6.8 million SPP. The company enters FY2027 with ~A$167 million of liquid funds and no drawn senior debt. The forward funding equation is the decisive issue: against a re-baselined A$699.2 million Stage Two budget, the company has stated that total available funding lines including the A$400 million government debt facility (subject to conditions precedent), undisbursed grants and the placement total roughly A$704 million (InvestSMART summary of the January 2026 announcement). That implies a thin margin over budget, with the A$80 million cost-overrun facility as part of the stack. The single most important monitorable is therefore Financial Close and first draw of the NAIF/EFA facilities, now targeted for Q4 CY2026.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Platform Details

PlatformContentsProducts / servicesStatus

HPA First Project (Stage One and Stage Two)

Gladstone HPA First Facility; Brisbane Product Development Centre

Ultra AAP / AAP-X / AAP-DP / AAP-D (alpha alumina), Ultra GAP / GAP-X (gamma alumina), Ultra ATH, Ultra ALN (Al-nitrate), nano-alumina, Ultra TAB (tablets)

Stage One operating (~380 tpa); Stage Two under construction

Alpha Sapphire

Two "Phase A" next-generation crystal growth units

Sapphire boules, 200 mm C-plane wafers

Qualification/small-scale sales; commercial-scale FID not yet taken

Revenue by Segment

MetricFY2024FY2025FY2026

Stage One sales revenue (AUD K)

56323556

Total statutory sales revenue (AUD K)

—318747

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Growth metric

Growth metricFY2025FY2026

Stage One sales growth YoY (%)

47672

Total statutory sales growth YoY (%)

—135.3

Key Financials

Metric (AUD Mn)FY2022FY2023FY2024FY2025FY2026

Net loss attributable to owners

-7.36-15.68-24.98-32.56-42.66

Income Statement and Per-Share Data

Metric (AUD Mn)FY2025FY2026

Sales revenue

0.3180.747

Other income

3.1072.904

Changes in inventories (expense)

-3.620-1.996

Raw materials and consumables

-0.366-0.931

Employee expenses

-12.912-16.142

Purchased services

-12.059-10.990

Depreciation and amortisation

-3.326-5.444

Repairs and maintenance

-2.160-1.658

Share-based payments

-4.273-5.053

Other expenses

-5.153-7.162

Unrealised gain/(loss) on investments

1.210-0.032

Loss before net finance income (operating result)

-39.234-45.757

Finance income

7.1663.514

Finance expense

-0.487-0.414

Loss before income tax

-32.555-42.657

Income tax expense

00

Net loss

-32.555-42.657

EBITDA (derived: operating result + D&A)

-35.908-40.313

EPS basic and diluted (A$ cents)

-2.87-3.42

Dividends per share (A$ cents)

00

Margin / growth metric

Margin / growth metricFY2025FY2026

Sales revenue growth YoY (%)

—135.3

Net loss growth YoY (%)

30.331.0

Balance Sheet

Metric (AUD Mn)FY2025FY2026

Total assets

283.371514.921

Cash and cash equivalents

102.036113.278

Term deposits (current + non-current)

5.25553.896

Total liquid funds (cash + term deposits)

107.291167.174

Property, plant and equipment

124.706292.460

Intangible assets (no goodwill)

3.5323.267

Trade and other receivables (current + non-current)

25.26115.688

Prepayments

13.91426.319

Inventory

4.3364.451

Total current assets

134.297201.729

Total current liabilities

50.56659.235

Working capital

83.731142.493

Other financial liabilities (QIC royalty instrument; FY2025 Sales Support Production Facility)

3.53425.919

Lease liabilities (current + non-current)

0.8822.355

Total debt-like liabilities

4.41628.274

Of which short-term

4.0831.173

Of which long-term

0.33227.101

Net cash (liquid funds less debt-like liabilities)

102.875138.900

Deferred grant recognition (current + non-current)

37.21823.857

Total liabilities

64.496103.834

Total equity

218.876411.088

Issued capital

352.718580.407

Accumulated losses

-137.875-180.531

Cash Flow

Metric (AUD Mn)FY2025FY2026

Net operating cash flow

-26.5-40.564

Payments for property, plant and equipment (capex)

—-162.119

Free cash flow (OCF less capex)

—-202.683

Government grants received (investing)

—10.912

Proceeds from equity issues

—231.873

Equity issue costs

—-8.105

QIC royalty investment (net)

—27.0

Dividends paid

00

Share buybacks

00

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2025FY2026

Return on equity (%) — on average equity

-14.0-13.5

Return on assets (%) — on average assets

—-10.7

Return on capital employed (%) — company-reported

-14-10

Current ratio (x)

2.663.41

Debt-like liabilities / equity (x)

0.0200.069

Net debt / EBITDA

Net debt / EBITDAn/m (net cash)n/m (net cash)

Interest coverage

n/m

n/m

Asset turnover (sales / average assets) (x)

—0.0019

Returns & Leverage Ratios (%)

Metric (%)FY2022FY2023FY2024FY2025FY2026

Company-reported ROCE (%)

-15-28-10-14-10

Country (% of FY2026 Shipment Quantity) Overview

Country (% of FY2026 shipment quantity)FY2026

South Korea

47.7

Japan

28.6

United States

10.9

Germany

5.3

Hong Kong

5.3

China

1.2

Spain

0.8

Australia

0.2

Regional Grouping Details

Regional grouping (% of FY2026 shipment quantity, derived)FY2026

North Asia (Korea, Japan, Hong Kong, China)

82.8

Americas (United States)

10.9

Europe (Germany, Spain)

6.1

Australia

0.2

Platform Details — HPA First — semiconductor

PlatformKoreaJapanUSEuropeChina / HKAustralia

HPA First — semiconductor (gamma alumina, GAP-X, ATH)

Primary

Primary

Emerging (equipment, CMP)

———

HPA First — chemicals / Al-nitrate

——

Yes (CMP, coatings, medical lasers)

Yes (aerospace coatings)

——

HPA First — LED

———

Germany

——

HPA First — catalysts

——

Yes (20 t open order)

———

HPA First — pharmaceutical

Yes

—————

Alpha Sapphire

———

Austria (wafers)

Boules, tablets

—

Research / aerospace

——

Yes

——

Yes

Per-Share Data

Metric (A$ per share)FY2021FY2022FY2023FY2024FY2025FY2026

Fiscal year-end share price (derived)

0.710.571.1650.880.870.665

Annual change in share price (reported)

—-0.1400.595-0.285-0.010-0.205

Return measure (to 30 June 2026, price only)

Value (%)

—————

1-year (FY2026)

-23.6—————

3-year (from 30 Jun 2023)

-42.9—————

5-year (from 30 Jun 2021)

-6.3—————

Valuation Snapshot

MultipleValueComment

Market capitalisation (AUD Mn)

~965

Derived

Enterprise value (AUD Mn)

~826

Market cap less net cash of A$138.9m

P/E

n/m

Loss-making

EV/EBITDA

n/m

Negative EBITDA

EV/Sales (x)

~1,100

Not meaningful as a valuation anchor

P/B (x)

~2.35

Book value ~A$0.283/share

EV / Stage Two budget (x)

~1.18

EV vs A$699.2m capex — an asset-based cross-check

Capital Markets

ItemStatus

Dividend history

Nil in every year FY2022–FY2026

Dividend policy

No dividends recommended; none expected pre-production

Credit ratings (Moody's / S&P / Fitch)

None — company is unrated

Debt Facilities

FacilityAmount (AUD Mn)Drawn at 30 Jun 2026 (AUD Mn)Tenor / maturity

NAIF/EFA Construction Facility

3200

11 years from Financial Close

NAIF/EFA Cost Overrun Facility

800

5 years from Financial Close

QIC royalty investment

3030

Royalty-based; carried at A$25.9m

Lease liabilities

2.42.4

Short-dated

Analyst Conclusions

Management guidance

No financial guidance. Operational guidance: Stage One upgrades complete October 2026; spray drying doubled by December 2026; NAIF/EFA first draw Q4 CY2026; major procurement complete by Q1 2027; balance of SMP and E&I contracts awarded in H2 CY2026; Stage Two first production late 2027 (some media cite completion late 2027 to early 2028); Al-nitrate supply to US Tier-1 CMP formulator from late CY2026; Stage Three concept studies ongoing.

Consensus growth expectations

Not publicly disclosed. Directionally, broker models imply revenue remaining sub-A$2m through FY2027 before stepping up with Stage Two ramp in FY2028.

Bull case

  1. Unique low-alpha moat meets an AI demand super-cycle. If the <1 ppb U/Th specification is genuinely unmatched at scale, Alpha sits in a price-insensitive, qualification-gated niche of AI packaging and HBM; LOIs already exceed nameplate (12,000 tpa vs 10,430 tpa) and the demand model points to 50,000 tpa by 2030.

  2. Fully funded on paper with sovereign anchors. ~A$167m liquid funds, A$400m undrawn senior debt (incl. A$80m overrun facility) and government equity create a deep-pocketed, policy-aligned shareholder base that lowers the probability of distressed funding.

  3. Mix and capacity upside. Stage One "as-built" outperformance supports a 12,230 tpa upside scenario and a mix tilt toward higher-value semiconductor products than the 2024 DFS assumed, plus Stage Three optionality.

Bear case

  1. Execution and cost risk on a 25–30x scale-up. A 26% re-baseline has already occurred before mechanical completion; SMP and E&I — historically the riskiest packages — were still being tendered in mid-2026.

  2. Financing conditionality and thin headroom. Financial Close has lagged Contractual Close by ~22 months; funding lines of ~A$704m roughly equal the A$699.2m budget, leaving little buffer before more equity is needed at depressed prices.

  3. Commercial conversion risk. LOIs are non-binding; achieved Stage One pricing (~US$26/kg) must hold at 10,000 tpa volumes, and incumbents may defend share; no binding Stage Two offtake was disclosed at 30 June 2026.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhy it matters
NAIF/EFA Financial Close and first drawQ4 CY2026Unlocks A$400m; removes the largest funding uncertainty
September 2026 quarterly reportBy 31 Oct 2026Capex run-rate, cash, contract progress
2026 AGMQ4 CY2026 (date not confirmed)Remuneration votes; strategy update
Conversion of LOIs into binding Stage One CY2027 and Stage Two contractsH2 CY2026–2027Validates revenue and pricing
Stage One upgrade completionOct–Dec 2026Revenue step-up in FY2027
SMP/E&I contract awards vs budgetH2 CY2026Tests the A$699.2m re-baseline
CMP Al-nitrate first commercial supply (US Tier-1)Late CY2026First scaled semiconductor chemical sale
Korean thermal filler qualification (1,200 tpa program)2026–2027Largest single semiconductor volume opportunity
Half-year FY2027 resultsFeb 2027Burn, balance sheet
Stage Three concept-study outputs2,027Growth optionality

Concluding analyst verdict

Alpha HPA is a high-conviction, high-variance industrial scale-up whose equity is effectively an option on two binary events: delivering a A$699 million plant to schedule in Gladstone, and converting a demonstrably large, AI-driven demand signal into binding, well-priced contracts. FY2026 materially de-risked the first event's funding dimension — A$225 million of new equity, a sovereign cornerstone in the NRFC, a fully drawn QIC instrument and ~A$167 million of liquid funds with no drawn bank debt — and maintained strong construction safety and procurement momentum. The commercial evidence also improved meaningfully: Stage One is sold out roughly threefold, LOIs exceed nameplate capacity, and the customer mix has rotated toward Japanese and Korean semiconductor packaging and US CMP formulators, where Alpha's ultra-low-alpha specification appears genuinely differentiated.

Against this, the record contains the warning signs typical of first-of-a-kind process plants: a 26% capex re-baseline, a long gap between Contractual and Financial Close on the senior debt, losses widening for a fifth consecutive year, and revenues that remain immaterial (A$0.75 million). Funding headroom over the re-baselined budget is slim, which makes the A$80 million cost-overrun facility a working part of the plan rather than a contingency. Governance is adequate for a company of this size but not best-practice: a non-independent executive Chair with related-party services, director-linked advisory fees, and an STI outcome that looks generous relative to missed milestones. Disclosure slips in the Appendix 4E reinforce the need for scrutiny.

At roughly A$0.8–1.1 billion of market value — around 1.2x the Stage Two budget on an EV basis — the market is pricing meaningful, but not full, success. The investment case strengthens decisively if the NAIF/EFA facilities close and are drawn in Q4 CY2026 and if the first binding semiconductor offtakes are signed before mechanical completion; failure on either front would likely force dilutive capital at unattractive prices. Verdict: speculative, execution-gated; monitor Financial Close and offtake conversion as the gating catalysts.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleDirector sinceBackground (summary)CommitteesOther listed boards

Norman Seckold

Chair (non-independent, executive consultancy arrangement)

30 Nov 2009

BEc (Sydney); 35+ years leading resource companies

—

Chair: Nickel Industries, Sky Metals, Fulcrum Lithium, Minerals Exploration

Robert Williamson

Managing Director

1 May 2023 (MD from 1 Feb 2025)

Mechanical engineer; 20+ years in industrial processing; previously VP & GM leading rebuild/commissioning of a 155 ktpa SX zinc refinery in the US; joined Alpha 2020

Risk & Sustainability; Nomination

—

Rimas Kairaitis

Executive Director & Chief Commercial Officer

1 Nov 2017 (MD until 1 Feb 2025)

Geologist; 30+ years; founding MD/CEO of Aurelia Metals

Nomination

Sky Metals

Dr Regan Crooks

Independent Non-Executive Director

6 Sep 2022

Chemical engineer; technology commercialisation; 7 years at Solvay leading R&D/commercialisation

Chair Audit; Remuneration; Risk & Sustainability

—

Marghanita Johnson

Independent Non-Executive Director

15 Jan 2024

CEO, Australian Aluminium Council since 2019; previously Rio Tinto government engagement, climate and sustainability roles

Chair Risk & Sustainability; Audit; Nomination

—

Annie Liu

Non-Executive Director

14 Dec 2023

Former Tesla strategic partnerships and global sourcing (battery, storage, solar); earlier Ford

Remuneration

—

Anthony Sgro

Non-Executive Director

1 Nov 2017

Chemical engineer; co-founded Kelair Pumps (1979, sold 2004)

Chair Nomination and Remuneration; Audit

—

Executive Leadership Team

NameTitleAppointedBackground

Robert Williamson

Managing Director

1 Feb 2025

As above

Rimas Kairaitis

Executive Director & CCO

1 Feb 2025 (CCO)

As above

Craig Jones

Chief Financial Officer

8 Jan 2024 (per Directors' Report; remuneration footnote says 8 Jan 2025)

25+ years banking/corporate finance; 18 years structured lending incl. ANZ; KPMG Corporate Finance; previously advised Alpha on HPA First financing

Peter Ware

Chief Operating Officer

22 Sep 2025

25+ years chemical manufacturing, mining, major hazard facilities in Australia and South Africa; previously VP (Operations / Australian Manufacturing) at Incitec Pivot

Richard Edwards

Company Secretary

3 Sep 2012

UNSW commerce; FGIA; CPA; also company secretary of Nickel Industries and European Resources

Robert Lord

Investor Relations

—

Named IR contact (Jul 2026 quarterly)

Directors' Remuneration

KMPSalary & feesOther benefitsSuperannuationShare-based paymentsTotal% performance-related

Norman Seckold

267,5000097,426364,92621.0

Robert Williamson

541,30045,41564,956229,550881,22119.5

Rimas Kairaitis

470,628-10,93856,475225,439741,60420.3

Anthony Sgro

103,341012,4010115,7420

Dr Regan Crooks

115,500000115,5000

Marghanita Johnson

115,5000043,367158,8670

Annie Liu

115,5000043,367158,8670

Craig Jones

388,8577,06946,663147,228589,81619.5

Peter Ware (from 22 Sep 2025)

318,53824,50238,22563,777445,0426.5

Total

2,436,66466,048218,720850,1543,571,58615.2

Board & Management Changes

DateChangeContext

8 Jan 2024

Craig Jones appointed CFO

Strengthen project-finance capability ahead of debt process

1 Feb 2025

Rob Williamson becomes MD; Rimas Kairaitis moves to Executive Director & CCO; Peter Nightingale resigns as director

Transition from developer/commercial leadership to construction/operations leadership

22 Sep 2025

Peter Ware appointed COO

Major-hazard-facility operating experience ahead of Stage Two commissioning

Major Shareholders

HolderSharesApprox. %Date / basisSource

Macquarie Group Ltd and controlled entities

100,041,0086.89

31 Jul 2026 (down from 8.23%)

Form 604 via Kalkine, 5 Aug 2026

National Reconstruction Fund Corporation

~100,000,000 (A$75m at A$0.75)

~6.9 (pro-forma)

Jan–Mar 2026 placement

Kalkine 30 Jan 2026

Norman Seckold (indirect, incl. pre-emptive right over 13.5m shares)

50,949,166

~3.5

31 Aug 2026

FY2026 Annual Report

AustralianSuper

—

Substantial (>5%) per company

Jan 2026

Placement announcement

Orica Limited

—

Substantial per company

Jan 2026

Placement announcement

Regal Partners Ltd

—

Previously substantial

Apr 2025

Simply Wall St insider log

Rimas Kairaitis

15,055,922

~1.0

31 Aug 2026

FY2026 Annual Report

Anthony Sgro

5,500,752

~0.4

31 Aug 2026

FY2026 Annual Report

Robert Williamson

1,812,807

~0.1

31 Aug 2026

FY2026 Annual Report

Competitive Landscape

Market Share by Competitor

CompetitorCountrySegment overlapRoute / positioningHPA-level revenue / share

Sumitomo Chemical

Japan

HPA (alpha alumina), fillers

Incumbent premium supplier; alkoxide route

Not disclosed at HPA level

Baikowski

France

HPA, CMP, LED, sapphire

Specialty alumina powders

—

Sasol (Ceralox / high-purity alumina)

Germany / South Africa

HPA, boehmite, catalysts

Alkoxide-based high-purity aluminas

Not disclosed at HPA level

Nippon Light Metal

Japan

High-purity alumina / hydroxide

Integrated aluminium chemicals

Not disclosed at HPA level

Chinese HPA producers (e.g., Hebei Pengda and peers)

China

4N–5N HPA, sapphire feedstock

Low-cost scale

—

Spherical alumina filler makers (e.g., Denka, Admatechs, Resonac)

Japan

Thermal fillers

Potential customers and competitors in downstream fillers

Not disclosed at product level

Altech Batteries (ASX: ATC)

Australia / Germany

HPA coatings (battery)

Kaolin-based HPA; pivoted toward battery products

—

Cadoux (formerly FYI Resources)

Australia

HPA

Kaolin-based HPA; A$3m WA grant for small plant

—

Andromeda Metals / Impact Minerals and other ASX juniors

Australia

HPA

Kaolin or alternative feeds; development stage

Pre-revenue

Monocrystal and Chinese sapphire growers

Russia / China

Synthetic sapphire

Low-cost scale

—

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricAlpha HPA (FY2026)Sumitomo ChemicalBaikowskiSasol (HPA business)

Revenue relevant to HPA

A$0.75m

Not disclosed at HPA level

—

Not disclosed at HPA level

Revenue growth

+135%———

Margins

n/m (pre-production)

———

R&D intensity

~534% of sales (cash R&D)

———

Route

Smart SX (nitric acid, solvent extraction)

Metal/alkoxide

Alum/other

Alkoxide

Ultra-low-alpha (U/Th <1 ppb)

Claimed unique

Not claimed in retrieved sources

Not claimed

Not claimed

“—” = not publicly disclosed.

Company Snapshot

130

Employees

2003

Founded

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • Differentiated purity profile: the company believes it is the only manufacturer globally capable of ultra-low-alpha HPA and ATH with U/Th <1 ppb (FY2026 Annual Report).
  • Proven process at small commercial scale: Stage One in continuous 24/7 production since late 2022 at ~380 tpa, de-risking process flows (FY2026 Annual Report, risk table).
  • Demand exceeds capacity: Stage One is ~3x oversubscribed and LOIs exceed 12,000 tpa vs ~10,430 tpa nameplate (June 2026 quarterly).
  • Strong liquidity and no drawn bank debt: A$167.2m cash and term deposits at 30 June 2026 against A$28.3m debt-like liabilities (FY2026 balance sheet).
  • Sovereign-capital backing: A$400m NAIF/EFA facilities, A$75m NRFC equity, A$30m QIC, A$45m MMI-C, A$21.7m Qld IPP, A$15.5m CMAI.
  • Safety and execution record: 607,000 Stage Two construction hours without a recordable injury in FY2026; 75 of 86 procurement packages awarded (Chair's Review).

Weaknesses

  • Immaterial revenue: A$747,150 in FY2026 vs operating result of -A$45.8m (income statement).
  • Cost overrun history: Stage Two capex re-baselined +26% from A$553m to A$699.2m in January 2026.
  • Widening losses: net loss up 31% to A$42.7m; five consecutive years of larger losses (FY2022 A$7.4m to FY2026 A$42.7m).
  • Governance features: non-independent Chair with related-party services (MIS Corporate A$222,000 FY2026); NED-related advisory fees (Alto Group A$181,834); STI paid at 64% despite missed financing/FID/offtake KPIs.
  • Disclosure quality slips: Appendix 4E headline loss and NTA unit errors; inconsistent CFO appointment date (FY2026 Annual Report).
  • Non-binding commercial book: LOIs reserve capacity post-qualification but are not offtake contracts; the FY2025 STI target of 10% offtake agreements was a stated objective.

Opportunities

  • AI semiconductor packaging: qualification with a Korean thermal filler maker supporting an initial 1,200 tpa program; HBM thermal paste testing with a global leader.
  • CMP: commercial terms with a US Tier-1 formulator for Al-nitrate (supply late CY2026); first nano-slurry orders.
  • Product-mix upside: Stage Two upside scenario of 12,230 tpa (+17%) from "as-built" performance.
  • Stage Three expansion: demand model >50,000 tpa by 2030.
  • Battery anchor: up to 5,000 tpa LOI with a Tier-1 Li-ion customer.
  • Adjacent niches: catalysts (180 tpa LOI), aerospace coatings, PFAS sorbents, GaN-on-sapphire wafers, low-carbon watch sapphire.

Threats

  • Financing conditionality: NAIF/EFA Financial Close still pending ~22 months after Contractual Close; first draw targeted Q4 CY2026 (June 2026 quarterly).
  • Thin funding headroom: available lines of ~A$704m against a A$699.2m budget (January 2026 announcement summary).
  • Ramp-up risk: Macquarie identifies Stage Two ramp-up and LOI conversion as the key risks to its thesis (July 2026 flashnote).
  • Competition: kaolin-HCl HPA routes; well-capitalised global entrants; Chinese/Russian sapphire pricing (risk table).
  • IP leakage: reliance on licence and trade-secret protection (risk table).
  • Share-price/market access: stock fell ~45% from its 2026 high of A$0.935 to a low of A$0.465 by July 2026, raising the cost of any further equity.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
7 Apr 2025Regal Partners substantial-holding changes (large buy and sell blocks recorded)Institutional register churn
1 May 2025Chair Seckold buys 350,000 shares and MD Williamson 50,000 shares at ~A$0.90Insider buying signal
30 Jun 2025Investor presentation: Stage Two 10,000 tpa; ESG positioningStrategy reiteration
Jul 2025Lease documents exchanged for new Brisbane siteR&D capacity
28–29 Jul 2025June 2025 quarter: FY2025 operating cash -A$26.5m; cash ~A$102m; LOIs for 62% of Stage Two; civils underwayPre-construction ramp
Aug 2025FY2025 results: net loss A$32.6mLoss widening
22 Sep 2025Peter Ware appointed COOOperational readiness
Oct 2025Binding documentation with QIC Fund to restructure A$30m investment into group-wide royaltyLiquidity
31 Oct 2025September quarter: three new semiconductor LOIs; nano-slurry high-volume manufacturing expected March 2026Semiconductor pivot
Nov–Dec 2025AGM; performance rights issued to executives (TSR-based); 371,172 and 220,000 shares issued on vestingGovernance
19 Dec 2025519,033 TSR rights and 150,000 service rights granted to COORetention
Jan 2026Stage Two re-baselined: capex A$553m to A$699.2m (+26%); first production late 2027Cost overrun; key negative
22 Jan 2026QIC facility fully drawn; cash ~A$39mFunding pressure
29 Jan 2026December quarter report; trading halt; A$225m placement launched at A$0.75 (11.2% discount)Capital raising
30 Jan 2026Placement completed; NRFC A$75m cornerstone; shares fell 13.6% to ~A$0.73Dilution vs de-risking
3 Feb 2026Tranche 1 (A$105m) settledFunding
6–20 Feb 2026SPP open/closed; raised A$6.8mRetail support
9 Feb 2026Investor presentation; broker research update on funding and re-baselineMarket communication
26 Feb 2026Half-year: loss A$22.5m (vs A$15.8m); sales A$263,616; cash A$45.1mBurn visibility
11–13 Mar 2026EGM approves Tranche 2 (A$120m); settlement 13 MarchFunding complete
30 Apr 2026March quarter: operating outflow A$11.4m; PP&E A$47.9m; cash A$211.7mPeak liquidity
1 May 2026Macquarie substantial-holder notice (8.23%)Register
28 May 2026Stormwater release exceedance at Stage Two site; compliance warning from Queensland DETSIMinor regulatory event
16 Jun 2026Product marketing update: LOIs >12,000 tpa; demand model >50,000 tpa by 2030Demand validation
Jun 2026Second of seven Queensland IPP milestone payments received (A$21.7m program)Grant flow
Jul 2026Nano-milling commissioning; additional jet mill commissionedStage One capability
22 Jul 2026June quarter: cash A$161.1m; capex A$45.8m; NAIF/EFA first draw targeted Q4 CY26; Stage One upgrades by Oct 2026; 130 orders from 52 end-usersExecution update
Post-30 Jun 2026First commercial Al-nitrate shipment to European aerospace coatings manufacturerNew market
29–31 Jul 2026Share price low ~A$0.465 on heavy volume (56.8m shares on 29 July); Macquarie reduces to 6.89%Sentiment trough
31 Aug 2026FY2026 Annual Report: loss A$42.7m; total assets A$514.9m; Stage Three concept studiesAnnual results
Pending (due by 31 Oct 2026)September 2026 quarterly report; 2026 AGM (date not confirmed)Next catalysts

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Sales revenue rose from AUD 0.3 Mn in FY2025 to AUD 0.7 Mn in FY2026.
Alpha HPA Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2025FY2026
Sales revenue0.30.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. 1Alpha HPA — 2026 Annual Report and Appendix 4E (ASX, via investorpa.com mirror) — 31 Aug 2026 — Financial statements, directors, remuneration, risks, operations
  2. 2Alpha HPA — Activities for the Quarter Ended 30 June 2026 and Appendix 4C (via investorpa.com) — 22 Jul 2026 — Cash flow, capex, re-baseline budget, product mix, orders, funding status
  3. 3Alpha HPA — Half-Year Report 31 December 2025 (ASX) — 26 Feb 2026 — Interim loss, balance sheet
  4. 4Alpha HPA — Placement completion announcement (ASX) — 30 Jan 2026 — Placement terms, timetable, funding lines
  5. 5Alpha HPA — Contractual Close announcement (ASX) — 17 Dec 2024 — NAIF/EFA facility structure
  6. 6Alpha HPA — FY2022 and FY2023 Annual Reports; quarterly reports (2021, 2022, 2024) — 2021–2024 — History, grants, Orica, Stage One
  7. 7Research note hosted on alphahpa.com.au ("A4N 09022026") — 9 Feb 2026 — DFS vs re-baseline capex
  8. 8Macquarie Research flashnotes hosted on alphahpa.com.au — 27 Feb 2025; 29 Jul 2025; 22 Jul 2026 — Cash flow FY2025, forecasts, rating/target, disclosures
  9. 9National Reconstruction Fund Corporation media release — Jan 2026 — Process description, Orica loop, funding
  10. 10Australian Manufacturing; ESD News; Aluminium Today; Grafa; TXF; NZEA — 2024–2026 — Employees, emissions claim, funding context
  11. 11Quartr event summaries (H1 and H2 FY2026) — Mar and Aug 2026 — Corroboration of results
  12. 12InvestSMART (share price history, announcement summaries, ETF holders) — 2025–2026 — Prices, quarterly summaries, ETF inclusion
  13. 13Simply Wall St (company profile, ownership/insider log) — 2026 — Former name, insider transactions, coverage count
  14. 14Kalkine (placement reaction; Macquarie Form 604) — Jan and Aug 2026 — Price reaction, NRFC stake, share count
  15. 15IBISWorld enterprise profile; PitchBook profile — 2026 — Incorporation date, former names, land purchase
  16. 16AustralianSuper Forms 603/605; Macquarie Form 603 (2023) — 2023–2024 — Substantial holder history
  17. 17ShareCafe; Alcircle/SMM — Apr–Dec 2024 — Debt package announcement
  18. 18Innovation News Network — 2022 — CMAI grant

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.